InDex Pharmaceuticals Holding AB's chances of survival looked slim after the late-stage failure of lead asset cobitolimod for ulcerative colitis but it seems as though the Swedish biotech will find salvation with a potential reverse merger.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?